Skip to main content
. 2017 Feb 24;8(17):27839–27853. doi: 10.18632/oncotarget.15711

Figure 4. Caspase-dependent apoptosis and cell proliferation in rituximab and cyclophosphamide alone or in combination-treated DLEU1-KD vs WT cells.

Figure 4

(A) Caspase 3/7 activity of rituximab (RTX, 10 ug/ml), cyclophosphamide (CTX, 10 mM) and RTX plus CTX combination (RTX/CTX) treated DLEU1-KD vs WT cells. (B) Cell proliferation of RTX, CTX and RTX/CTX treated DLEU1-KD vs WT cells. (C, D) The mRNA (C) and protein (D) expression of anti-apoptotic genes in RTX treated DLEU1-KD vs WT cells. Data are represented as the mean ± SD of triplicates (paired t test). *p < 0.05.